To quantify SOX2 expression in GBMs and in brain tumour cell lines, the amount of transcripts was determined in nine tumour specimens from GBM patients from the Department of Neurosurgery and in one commercially available sample from a malignant glioma patient by real-time PCR. This evidence concerns the gene SOX2 and glioblastoma.